Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India

• DOI: 10.3332/ecancer.2022.1450
• Publication Date: 2022-09-26T13:16:31Z
• Authors: Sandip Ganguly; Navonil Mukherjee; Sayan Mandal; Somnath Roy; Sanjit Agarwal; Bivas Biswas; Joydeep Ghosh
• Keywords: Palbociclib; Cyclin-dependent kinase 4

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have shown marked benefit in the treatment of hormone positive metastatic breast cancer (HR+ MBC). There are limited real-world studies with palbociclib and ribociclib. Here we report our experience CDK4/6 these groups patients.Patients HR+ MBC who received either or ribociclib during course their from January 2017 to 2022 were included study. The baseline demographic features, details toxicity recorded. Patients at least 1 month therapy survival analysis.A total 144 patients time period. median age population was 53 (30-80) years. Ninety-eight (71.4%) presented de novo disease. most common site metastasis skeleton (74.2%). Most (75%) as therapy. At a follow-up 20.2 months, progression free (PFS) whole 16.5 (95% confidence interval CI): 11.6-25.5) months overall (OS) 29.7 CI: 21.7-44.6) months. presence liver metastases, low progesterone receptor positivity (Allred score < 6) prior systemic poor prognostic factors for both PFS OS multivariate analysis. Drug discontinued only 2.1% patient population.Use has led improvement it is well tolerated. metastases factors.